Ensheng Medical Secures Tens of Millions RMB in Pre-A+ Funding to Advance Peripheral Venous Intervention Solutions

VCBeat (WeChat ID: Vcbeat) has learned that Shanghai Ensheng Medical Technology Co., Ltd. (“Ensheng Medical”), a portfolio company of Ruiling Capital, recently announced the completion of a tens-of-millions-yuan Pre-A+ financing round led by Jiuzhi Xinfei. The proceeds will be primarily used to accelerate the R&D of interventional medical devices for venous vascular diseases, advance clinical trials, and strengthen the R&D team. Previously, Ensheng Medical had received early-stage investments from Furong Capital and Haimaide Venture Capital.

Shanghai Ensheng Medical Technology Co., Ltd., established in November 2018, is a high-tech enterprise dedicated to providing comprehensive solutions for venous diseases. Adhering to the corporate philosophy of “Benefiting the Public with Grace, Earning Reputation with Integrity,” the company leverages internationally advanced, independently owned innovative technologies to deliver high-quality, high-performance peripheral venous medical products to patients, striving to create “new domestic brands” in interventional medical devices. In just over two years, the company has developed a comprehensive treatment regimen for lower extremity venous disorders, addressing multiple indications such as varicose veins and pulmonary embolism, and has expanded its scope to the entire peripheral vascular field. This achievement holds milestone significance within the industry and has propelled the development of China’s venous disease sector.

In China, the large patient population with venous diseases contrasts with the relatively low maturity of venous intervention therapy development, due to insufficient market education and a lack of high-performance products. Multinational companies such as Boston Scientific and Cook Medical dominate the market, while no leading domestic products have yet been launched. Imported devices are expensive, with individual stents often costing tens of thousands of yuan, imposing a significant financial burden on patients. Furthermore, these devices fail to fully meet clinical needs due to design limitations. For instance, there is a clinical demand for stents used in the treatment of iliac vein compression that offer both excellent radial strength and flexibility; however, currently available imported stents in China do not satisfy these requirements.

Wang Shengqiang, Founder and CEO of Ensheng Medical, stated, “Ensheng Medical’s mission is to respond to the national call and practice inclusive healthcare. Independent research and development build our core competitiveness, while our team of industry veterans ensures that R&D achievements are rapidly translated into productive capabilities. We develop venous disease treatment products that truly meet clinical needs, providing Chinese patients with high-quality, affordable vascular interventional medical devices.”

Currently, the peripheral venous intervention market is still dominated by imported products. The founder and team of Ensheng Medical possess a spirit of continuous breakthrough and progress, as well as the ability to iterate and innovate products. We believe that the company has the capability to break the import monopoly in the field of peripheral interventions and become the most representative leading enterprise in this sector.

RuiLing Capital, established in July 2018, is a boutique financial advisory (FA) firm primarily providing equity-related financing, investment, and financial consulting services to healthcare companies from the Pre-A to Series C stages. The team comprises seasoned investment banking and investment professionals in China, equipped with mature methodologies and a comprehensive service workflow. It precisely connects clients with high-quality resources while supporting business development to enhance company valuation. To date, the firm has served dozens of enterprises and facilitated investment transactions totaling hundreds of millions of yuan.